Nectin Therapeutics

Today we are honored to announce a global license agreement with Immunome, Inc. Under the terms of the license, Immunome received exclusive rights to a panel of antibodies targeting a novel undisclosed target. “This agreement allows Nectin Therapeutics to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need, in parallel to advancing our novel #ADCs into clinical development. Immunome’s leadership team’s track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets,” said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics. “Immunome believes the next generation of transformative antibody-drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “We appreciate the work Nectin has done on these antibodies and look forward to advancing them further.” To read about the news: https://lnkd.in/g68U9GBf #CancerResearch #Immunotherapy #Biotechnology

Honored to announce that Nectin Therapeutics has been awarded a €2.5M grant first and potentially up to €15M in equity from European Innovation Council and SMEs Executive Agency (EISMEA). In a competitive field of 1083 proposals, we are proud to be among the 42 recipients of EIC funding, highlighting the promise of our innovative #cancerimmunotherapy pipeline. We extend our gratitude to the team of the #eicaccelerator for this recognition and support and look forward to accelerating our programs for patients in need. https://lnkd.in/dxDKsB2h

Meet Dr. Alon Vitenshtein, PhD - Senior Scientist at Nectin Therapeutics What's the best way to cure – or even treat – cancer? Chemotherapy and other standard therapies have helped many, but there are cancers that don’t respond well - or at all - to those treatments in some patients. About 80% of patients do not respond to approved immuno-oncology therapies. According to Dr. Alon Vitenshtein, these patients may be helped with the breakthroughs he and the team have been working on at Nectin Therapeutics. Dr. Vitenshtein appreciates Nectin for two reasons – one, the innovative and highly promising therapeutics the company is developing to treat cancer. And two, as a previous founder of two AI/ML startups in the field of life science, he appreciated and was inspired by the perseverance of the company's founder and chief scientific officer, Dr. Pini Tsukerman, who promoted the idea of targeting PVR (CD155), a key immune checkpoint, as a way to block the growth of tumors. “While as scientists we are all trained to follow the data, in reality, very few can persevere with a truly novel idea if it goes head on with scientific consensus. And that is exactly what Dr. Tsukerman did, introducing a new paradigm that has now been also observed and accepted by the scientific community worldwide” Dr. Vitenshtein says. Dr. Vitenshtein, who earned his bachelor’s and master’s degrees from the Technion and a doctorate at Hebrew University was recruited to work at Nectin by Dr.Tsukerman, who he had kept in touch with throughout the years. “We are currently in the development stage, but our pipeline holds so much promise,” Dr. Vitenshtein says. Working at Nectin has provided him with life lessons, too. “Our work shows that you have to let the science lead you,” he says. “To me, it's inspiring to see how the founding team persevered. I am thrilled to be a part of an effort working on novel approaches that we hope will deliver a range of groundbreaking efficacious therapeutics for cancer patients.” #cancerresearch #nectin #immunooncology